Package
- Sanofi
Latest Sanofi Patents:
- Isoxazolidines as RIPK1 inhibitors and use thereof
- Packaging assembly
- Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
- ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATES AND ANTI-VEGFR-2 ANTIBODIES
- POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
Description
Claims
The ornamental design for a package, as shown and described.
Referenced Cited
U.S. Patent Documents
Other references
| D87781 | September 1932 | Hauck |
| D98468 | February 1936 | Wandel |
| D323618 | February 4, 1992 | Arai |
| D362620 | September 26, 1995 | Nagasaka |
| D364346 | November 21, 1995 | Yamada |
| D364805 | December 5, 1995 | Hata |
| D366415 | January 23, 1996 | Nagasaka |
| D391481 | March 3, 1998 | Oxley |
| D396806 | August 11, 1998 | Burke |
| D419443 | January 25, 2000 | Yonehara |
| D719032 | December 9, 2014 | Kanda |
| D719462 | December 16, 2014 | Kanda |
- Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients. [online] Published Jul. 24, 2015. Retrieved from URL: <http://www.multivu.com/players/English/7500451-sanofi-praluent-fda-approval/>.
Patent History
Patent number: D764289
Type: Grant
Filed: May 12, 2015
Date of Patent: Aug 23, 2016
Assignee: Sanofi (Paris)
Inventors: Claudia Hauck (Paris), Helene Capgras (Paris), Noriko Hattori (Tokyo), Cristina Fernandez (Paris)
Primary Examiner: Vy Koenig
Application Number: 29/526,612
Type: Grant
Filed: May 12, 2015
Date of Patent: Aug 23, 2016
Assignee: Sanofi (Paris)
Inventors: Claudia Hauck (Paris), Helene Capgras (Paris), Noriko Hattori (Tokyo), Cristina Fernandez (Paris)
Primary Examiner: Vy Koenig
Application Number: 29/526,612
Classifications
Current U.S. Class:
D9/432